Big-cap device makers on European exchanges did nicely in 2021, whereas their US-listed brethren had a harder time.
Shareholders are rewarding the kinds of companies they punished a year ago.
A lot of money is sloshing around, and medical device start-ups are reaping the benefits.
The Verily subsidiary has the luxury of patient backers. But hungrier rivals could steal a march.
It takes more than a pandemic to stop medical device companies merging.
In the second half of 2020 medtech began a tentative – and possibly short-lived – recovery.
The purchase of Livongo is the richest healthcare deal this year, but questions about reimbursement, competition and profitability remain.
2019 was an average year for medtech M&A. 2020, not so much.